DISCLOSED IS A PHARMACEUTICAL COMPOSITION OF A HEPATITIS C VIRAL PROTEASE INHIBITOR WHICH IS SUITABLE FOR ORAL ADMINISTRATION VIA A LIQUID- OR SEMI-SOLID-FILED CAPSULE AND METHODS OF USING THIS COMPOSITION FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS (HCV) AND FOR THE TREATMENT OF AN HCV INFECTION. THE LIQUID- OR SEMI-SOLID PHARMACEUTICAL COMPOSITION OF THE PRESENT INVENTION COMPRISES A COMPOUND OF FORMULA 1, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, TOGETHER WITH ONE OR MORE PHARMACEUTICALLY ACCEPTABLE LIPIDS AND HYDROPHILIC SURFACTANTS.
